Stephen Rossi, Pharm.D. joined Pliant in 2020 as Vice President, Clinical Development and is responsible for leading the clinical development teams for the PLN-74809 programs. Dr. Rossi brings over 25 years of liver disease experience in biologics, small molecules and diagnostics. Prior to joining Pliant, he was Vice President, Clinical Development at CymaBay Therapeutics overseeing the NASH, PSC and Clinical Pharmacology programs for seladelpar. Previously, he led the NASH, PSC and PBC programs for aldafermin at NGM Bio for 5 years. Additional prior experience in liver diseases and HIV included roles at Gilead Sciences, Roche Molecular and Roche Pharmaceuticals where he held senior roles in both clinical development and medical affairs. Dr. Rossi provided clinical and research support for the liver and kidney transplant teams at University of Cincinnati and University of Michigan prior to holding a national leadership position with the VA Healthcare Systems Hepatitis C program.
Dr. Rossi earned a A.B. from the University of California at Davis and his Pharm.D. from the University of California at San Francisco.